欧盟批准了较高的肥胖 Wegovy剂量,在临床试验中增加了体重下降。 The EU approved a higher Wegovy dose for obesity, boosting weight loss in clinical trials.

欧洲联盟委员会已核准对肥胖成人使用高剂量7.2毫克的诺沃·诺迪斯克Wegovy,允许每周一次性注射三2.4毫克剂量。 The European Commission has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy for adults with obesity, allowing a single weekly injection of three 2.4 mg doses. 对于已经使用2.4毫克剂量至少4周并需要进一步减肥的病人来说, The option is for patients who’ve already used the 2.4 mg dose for at least four weeks and need further weight loss. 临床试验显示,在18个月的时间里,体重平均减少了21%,大约三分之一的人体重减少了25%或以上。 Clinical trials showed an average 21% body weight reduction over 18 months, with about one in three losing 25% or more. 该批准遵循联合王国的类似决定,正等待美国林业发展局的审查。 如果获得批准,欧盟今年晚些时候可能会推出7.2毫克的专用笔。 The approval follows similar decisions in the UK and is pending FDA review in the U.S. A dedicated 7.2 mg pen may launch in the EU later this year if approved.